MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells

doi:10.3748/wjg.v25.i22.2752

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 22

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7512)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

534

WORD

251

HTML

4109

Figures (1-6)

333

Sum=5227

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

900

Download

1385

Sum=2285

Jun 14, 2019 (publication date) through Nov 2, 2024

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jun 14, 2019; 25(22): 2752-2762
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2752

Full Size Figure Download Figure

Figure 3 Growth inhibition rate of HepG2 cells treated with LV-hsa-mir-34a transfection combined with doxorubicin. Dox: Doxorubicin.

Citation: Zheng SZ, Sun P, Wang JP, Liu Y, Gong W, Liu J. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World J Gastroenterol 2019; 25(22): 2752-2762
URL: https://www.wjgnet.com/1007-9327/full/v25/i22/2752.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i22.2752